Aurobindo Pharma Ltd (AUROPHARMA)
₹1,681.40
Mkt cap
₹96,744 Cr
P/E ratio
25.60
P/B
2.58
Div yield
0.24%
ROE
10.10%
ROCE
12.90%
EPS (TTM)
₹65.68
Book value
₹652
52W range
1,080–1,740
Sector
Healthcare
Price history
Previous close
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
NSE AUROPHARMABSE 524804
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−3.37% from high₹1,681
₹1,080+55.67% from low₹1,740
Current
₹1,681.40
Prev close
₹1,659.90
Day
+1.30%
Price performance
1D
+1.30%
1W
+6.98%
1M
−0.96%
3M
+6.67%
6M
+20.38%
1Y
+52.98%
YTD
+38.34%
Financials
Revenue, profit & margin
P/E ratio
25.6×
AUROPHARMA is 26% below the sector median of 34.4×
AUROPHARMA25.6×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,851 | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 | |
| Expenses | 5,702 | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 | 7,271 | |
| Operating Profit | 1,149 | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 | 1,880 | |
| OPM % | 17% | 19% | 22% | 22% | 21% | 20% | 20% | 21% | 20% | 20% | 21% | 20% | 21% | |
| Other Income | 47 | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 | 123 | 117 | 224 | |
| Interest | 57 | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 | |
| Depreciation | 327 | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 | |
| Profit before tax | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,515 | |
| Tax % | 30% | 30% | 26% | 26% | 31% | 32% | 30% | 32% | 32% | 34% | 32% | 29% | 32% | |
| Net Profit | 570 | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 | |
| EPS in Rs | 9.74 | 12.92 | 15.98 | 15.51 | 15.69 | 14.07 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.95 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
4 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.06% · closed higher next day 29 of last 61
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Nov '23 | 10 Feb '24◦ | 25 May '24◦ | 10 Aug '24◦ | 9 Nov '24◦ | 6 Feb '25◦ | 27 May '25 | 4 Aug '25◦ | 5 Nov '25◦ | 9 Feb '26◦ | 21 May '26◦ | 5 Aug '26◦ |
| Earnings day | +3.04% | +1.55% | −3.13% | +0.83% | −2.90% | −0.01% | +0.87% | −1.02% | −0.74% | −6.61% | −5.38% | −1.52% |
| +1 day | +3.03% | +2.32% | −1.14% | +3.87% | −4.53% | −1.23% | −2.80% | −1.66% | −2.20% | −4.74% | −5.95% | +2.76% |
| +5 days | +4.98% | +3.76% | −0.62% | +6.04% | −5.83% | −5.07% | −3.14% | −2.95% | +5.32% | −1.41% | −7.31% | +3.10% |
| +15 days | +7.91% | +8.75% | +0.62% | +6.88% | −5.13% | −10.85% | −6.03% | −5.88% | +7.55% | −0.69% | −8.95% | +1.46% |
| +30 days | +12.50% | +6.70% | +7.88% | +3.55% | −5.37% | +0.26% | −2.81% | +3.53% | +5.24% | +8.65% | +2.35% | +7.47% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.88%Promoter
Promoters51.88%
FIIs17.41%1.03
DIIs24.37%0.68
Public6.29%0.34
Government0.05%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Aurobindo Pharma | ₹1,681.40 | 25.59 | 96,744 | 0.24% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts121
TranscriptAug 2026PPTAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024TranscriptFeb 2024PPTFeb 2024TranscriptNov 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Oct - Aurobindo Pharma schedules Q2FY27 earnings call on November 5, 2026 at 8:30 AM IST.Board Meeting Intimation for Intimation Of Board Meeting 26 Oct - Board meeting on November 4, 2026 to approve Q2/H1 FY27 results and consider interim dividend.Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Oct - Submission of Notice published in newspapers.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 5 Oct - Regulation 74(5) certificate filed for quarter ended September 30, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 3 Oct - USFDA final approval received for Perampanel Tablets; launch planned in Q3FY27.